Molecular Targeting Technologies, Inc.

16 articles with Molecular Targeting Technologies, Inc.

• MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial

  6/29/2022

  Molecular Targeting Technologies, Inc. (MTTI), announced that the first patient has been dosed in a clinical trial of EBTATE ( 177 Lu-DOTA-EB-TATE) for the treatment of patients with advanced, well differentiated neuroendocrine tumors.

• Molecular Targeting Technologies, Inc. Features EBTATE Advances at The 2022 SNMMI Meeting In Vancouver, BC

  6/9/2022

  Molecular Targeting Technologies, Inc. (MTTI), a clinical stage oncology company, will highlight advances on its EvaThera TM radiotheranostics platform at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Vancouver, BC, on June 11-15, 2022.

• MTTI and ITM Sign Clinical Supply Agreement for n.c.a. Lutetium-177

  4/13/2022

  Molecular Targeting Technologies Inc. and ITM Isotope Technologies Munich SE announced the signing of a global clinical supply agreement that provides MTTI with ITM’s medical radioisotope no-carrier-added lutetium-177 for the preclinical and clinical development as well as potential commercial production of MTTI’s radiopharmaceutical candidate n.c.a.

• Molecular Targeting Technologies, Inc., Thomas Jefferson University and North China Pharmaceutical Co., Ltd Announced the Chinese Approval for a Rabies Drug

  1/26/2022

  Molecular Targeting Technologies, Inc., (MTTI) announced that the Chinese NMPA has approved a rabies virus neutralizing, fully human antibody, Ormutivimab for post-exposure prophylaxis.

• MTTI partners with Evergreen to manufacture EvaThera platform of radiopharmaceuticals

  12/1/2021

  Molecular Targeting Technologies, Inc. (MTTI) and Evergreen Theragnostics, Inc., today announced an agreement in which Evergreen will manufacture MTTI's EvaThera™ platform of radiopharmaceuticals.

• Molecular Targeting Technologies, Inc. Announces Spray Technology That Lights Up Tumors

  10/19/2021

  Molecular Targeting Technologies, Inc. (MTTI) announce publication of their Spray technology in ACS Sensors, entitled “Near-Infrared Fluorogenic Spray for Rapid Tumor Sensing.”

• Molecular Targeting Technologies, Inc. and University of Antwerp Begin First-in-Human Study of TDURA Diagnostic for Early Detection of Response to Colon Cancer Therapy

  5/11/2021

  Molecular Targeting Technologies, Inc. (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA ( 99m Tc-Duramycin), in patients with advanced colorectal cancer (CRC)*.

• Molecular Targeting Technologies, Inc. Receives Global Rights From NIH for Integrin-Targeting Radiotherapeutics to Treat GBM and Lung Cancer

  10/28/2019

  The key feature of this technology is the incorporation of a derivative of Evans Blue into RGD peptide radiopharmaceutical which binds to both albumin and integrin thus extends residence time, enabling smaller and less frequent dosing.

• Early Studies Show EBTATE is Well Tolerated and Effective in Treating Neuroendocrine Tumors

  6/24/2019

  Talk entitled “Safety and Response of an Evans Blue-modified 177Lu-labeled Octreotate (EBTATE) in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study” at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Anaheim this June*.

• Molecular Targeting Technologies, Inc. Wins Exclusive License for Novel Neuroendocrine Neoplasm Drug from NIH

  10/8/2018

  This patent estate invented by Drs. Xiaoyuan Chen and Orit Jacobson covers a radiotherapeutic with potential uses for treating Neuroendocrine Neoplasms

• Molecular Targeting Technologies, Inc. Receives Expanded Patent Approval For 99mTC-Duramycin Technology To Target Programmed Cell Death

  5/18/2015

• Molecular Targeting Technologies, Inc. And National Health Research Institutes Present A Novel Cancer Therapeutic At 2015 American Association for Cancer Research

  4/17/2015

• Molecular Targeting Technologies, Inc. And National Health Research Institutes Have Joined Forces In Developing Novel Cancer Therapeutics

  8/5/2014

• Molecular Targeting Technologies, Inc. Release: Real Time Assessment of Tumor Response Presentation Wins Innovation Competition at 2013 SNMMI Meeting

  6/25/2013

• Molecular Targeting Technologies, Inc. Licenses Robust Near-infrared (NIR) Dye Technology from the Massachusetts General Hospital/Harvard Medical School

  5/10/2011

• Molecular Targeting Technologies, Inc. Licenses Cell Targeting Technology from the Molecular Targeting Technologies, Inc.

  3/1/2010